[go: up one dir, main page]

BR112015025915A8 - uso de composto para redução de gordura e composições - Google Patents

uso de composto para redução de gordura e composições Download PDF

Info

Publication number
BR112015025915A8
BR112015025915A8 BR112015025915A BR112015025915A BR112015025915A8 BR 112015025915 A8 BR112015025915 A8 BR 112015025915A8 BR 112015025915 A BR112015025915 A BR 112015025915A BR 112015025915 A BR112015025915 A BR 112015025915A BR 112015025915 A8 BR112015025915 A8 BR 112015025915A8
Authority
BR
Brazil
Prior art keywords
compositions
fat reduction
fat
reduction compound
sustained release
Prior art date
Application number
BR112015025915A
Other languages
English (en)
Other versions
BR112015025915A2 (pt
Inventor
F Woodward David
M Hughes Patrick
M Whitcup Scott
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112015025915A2 publication Critical patent/BR112015025915A2/pt
Publication of BR112015025915A8 publication Critical patent/BR112015025915A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)

Abstract

liberação sustentada de bimatoprosta, análogos de bimatoprosta, prostamidas e prostaglandinas para redução de gordura resumo a presente invenção orienta-se a composições e métodos para injeção em depósitos de gordura para liberação sustentada de compostos que resultam na redução da gordura localizada.
BR112015025915A 2013-04-12 2014-04-09 uso de composto para redução de gordura e composições BR112015025915A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361811682P 2013-04-12 2013-04-12
PCT/US2014/033558 WO2014169075A1 (en) 2013-04-12 2014-04-09 Sustained release of bimatoprost, bimatoprost analogs, prostamides and prostaglandins for fat reduction

Publications (2)

Publication Number Publication Date
BR112015025915A2 BR112015025915A2 (pt) 2017-07-25
BR112015025915A8 true BR112015025915A8 (pt) 2020-01-14

Family

ID=51686960

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025915A BR112015025915A8 (pt) 2013-04-12 2014-04-09 uso de composto para redução de gordura e composições

Country Status (18)

Country Link
US (2) US20140308354A1 (pt)
EP (2) EP3656375A1 (pt)
JP (1) JP2016520561A (pt)
KR (1) KR20150141972A (pt)
CN (2) CN110840899A (pt)
AU (2) AU2014250937A1 (pt)
BR (1) BR112015025915A8 (pt)
CA (1) CA2908731A1 (pt)
CL (1) CL2015003023A1 (pt)
DK (1) DK2983663T3 (pt)
ES (1) ES2785382T3 (pt)
IL (1) IL242006B (pt)
MX (1) MX381097B (pt)
MY (1) MY187802A (pt)
RU (1) RU2015143859A (pt)
SG (2) SG10201701938PA (pt)
WO (1) WO2014169075A1 (pt)
ZA (1) ZA201507217B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6796601B2 (ja) * 2015-04-30 2020-12-09 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 脂肪を低減させるための美容上の方法及び治療用途
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
BR112023001073A2 (pt) * 2020-07-21 2023-03-07 Allergan Inc Implante intraocular com alto carregamento de prostamida
WO2024218609A1 (en) * 2023-04-18 2024-10-24 Welfare Concepts Limited Composition and method for inducing luteolysis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2218424A (en) * 1931-05-07 1940-10-15 Teleregister Corp Transmitter and code translator
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
JPH11505802A (ja) * 1995-05-18 1999-05-25 アラーガン 高眼圧処置剤としてのシクロペンタンヘプタン（エン）酸，２−ヘテロアリールアルケニル誘導体
AU2003274735B2 (en) 2002-10-23 2008-12-04 Sucampo Ag Prostaglandin compounds for the treatment of obesity
KR20050085367A (ko) * 2002-12-04 2005-08-29 산텐 세이야꾸 가부시키가이샤 결막하 데포에 의한 약물 송달 시스템
JP2007515494A (ja) * 2003-12-22 2007-06-14 アベンティス・ファーマスーティカルズ・インコーポレイテツド 注射可能なフォスファチジルコリン調製物
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
CA2681668C (en) * 2006-03-23 2014-04-01 Michael S. Singer Compositions comprising prostaglandin f2-alpha analogs and methods for reducing body fat
US20100119609A1 (en) * 2006-10-17 2010-05-13 John Daniel Dobak Methods, compositions, and formulations for the treatment of thyroid eye disease
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US20130071349A1 (en) * 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
WO2012012546A2 (en) 2010-07-21 2012-01-26 Allergan, Inc. METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
TWI722298B (zh) * 2013-03-15 2021-03-21 美商歐樂根公司 含有前列醯胺之眼內植入物
JP6796601B2 (ja) 2015-04-30 2020-12-09 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 脂肪を低減させるための美容上の方法及び治療用途

Also Published As

Publication number Publication date
MX381097B (es) 2025-03-12
US10682361B2 (en) 2020-06-16
NZ712804A (en) 2021-02-26
EP2983663A1 (en) 2016-02-17
MY187802A (en) 2021-10-26
IL242006B (en) 2020-04-30
AU2014250937A1 (en) 2015-10-22
HK1221406A1 (en) 2017-06-02
KR20150141972A (ko) 2015-12-21
EP2983663B1 (en) 2020-01-22
BR112015025915A2 (pt) 2017-07-25
US20160339039A1 (en) 2016-11-24
RU2015143859A (ru) 2017-05-16
MX2015014320A (es) 2015-12-08
RU2015143859A3 (pt) 2018-03-05
WO2014169075A1 (en) 2014-10-16
EP3656375A1 (en) 2020-05-27
AU2019203214B2 (en) 2020-10-29
US20140308354A1 (en) 2014-10-16
AU2019203214A1 (en) 2019-05-30
CN105101962A (zh) 2015-11-25
CL2015003023A1 (es) 2016-06-10
DK2983663T3 (da) 2020-04-20
ES2785382T3 (es) 2020-10-06
ZA201507217B (en) 2017-09-27
CA2908731A1 (en) 2014-10-16
JP2016520561A (ja) 2016-07-14
SG10202109919PA (en) 2021-10-28
SG10201701938PA (en) 2017-04-27
CN110840899A (zh) 2020-02-28

Similar Documents

Publication Publication Date Title
CL2019003657A1 (es) Anticuerpos que se unen específicamente a cd38 útiles para mejorar una respuesta inmune en un paciente. (divisional solicitud 201703275)
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CL2015003270A1 (es) Composiciones y métodos para el suministro tópico de prostaglandinas a la grasa subcutanea.
MX2018003827A (es) Anticuerpos anti-cd19 humano con alta afinidad.
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
BR112014012449A2 (pt) método para produção de um cabo de escova de dentes que tem uma cavidade interna
BR112015019817A2 (pt) interface de vedação para um compartimento de telecomunicações
EA201690582A1 (ru) Модуляторы фактора в комплемента
BR112015027432B8 (pt) 3-(4-isobutil-2-metilfenil)propanal como ingrediente de perfume
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
BR112015023142A2 (pt) moduladores de p2x7
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
MX338078B (es) Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos.
MX2018006392A (es) Metodo para la preparacion de compuestos que tienen un andamiaje de 16-oxabiciclo[10.3.1]pentadeceno y productos subsecuentes de estos.
CO2018004581A2 (es) Compuestos de criptoficina y productos conjugados, y sus métodos de preparación
BR112015008117A2 (pt) benzamidas
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
BR112014019458A8 (pt) Corpo tubular, e, cárter para motores
BR112016007068A2 (pt) ?composições cosméticas?
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue
BR112015025915A8 (pt) uso de composto para redução de gordura e composições
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
BR112014017587A8 (pt) métodos e formulações para o tratamento de deficiências de ácido siálico
BR112016013992A2 (pt) Composição cosmética
TWD187972S (zh) 泵桿式制動器

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time